Pediatric Advisory Committee To Review Postmarketing Safety Data For 16 Products
This article was originally published in The Pink Sheet Daily
FDA committee will examine QT prolongation signal seen in safety review of Forest’s Celexa.
You may also be interested in...
Neuropsychiatric adverse event reports for Roche's antiviral jump in most recent review, prompting FDA staff to suggest a labeling change.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.